BackCellectis Overview
Cellectis - ADR

Cellectis Target Price

Analysts' average 12-month price target for Cellectis is $9.

Get informed when a big investor buys or sells

+ Follow

Share Price

$3.11

Average Target Price

$9.00189.4% upside

1 analysts in the last 4 months

High: $9 | Low: $9

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-05-28BarclaysLukas Shumway$9189.4% upsideOpen
2025-10-20Wells FargoNick Abbott$428.6% upsideOpen
2025-10-17BarclaysGena Wang$8157.2% upsideOpen

Cellectis (CLLS) FAQ

Cellectis posts a target price of $9. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $9 for CLLS means covering analysts, on average, see the stock 189.4% upside of $3.11 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for CLLS's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Cellectis's other metric pages and overview cover the third.

Judging Cellectis against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $9 here, then scan peer and history charts to see if the gap is persistent.